PRLD
HEALTHCAREPrelude Therapeutics Inc
$4.84+0.17 (+3.64%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving PRLD Today?
No stock-specific AI insight has been generated for PRLD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.75$5.54
$4.84
Fundamentals
Market Cap$385M
P/E Ratio—
EPS$-1.29
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin—
Debt / Equity—
Trading
Volume708K
Avg Volume (10D)—
Shares Outstanding64.9M
PRLD News
20 articles- Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a BetYahoo Finance·May 8, 2026
- Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast CancerYahoo Finance·May 1, 2026
- Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026GlobeNewswire Inc.·Apr 20, 2026
- Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical OfficerYahoo Finance·Apr 15, 2026
- Myriad Genetics And 2 Other Penny Stocks To Watch CloselyYahoo Finance·Apr 6, 2026
- Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual MeetingYahoo Finance·Mar 17, 2026
- Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026Yahoo Finance·Mar 10, 2026
- Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFOYahoo Finance·Feb 26, 2026
- Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F InhibitorYahoo Finance·Feb 3, 2026
- Definitive Healthcare And 2 Other Promising Penny StocksYahoo Finance·Jan 28, 2026
- Retail investors in Prelude Therapeutics Incorporated (NASDAQ:PRLD) are its biggest bettors, and their bets paid off as stock gained 12% last weekYahoo Finance·Jan 26, 2026
- December 2025's Intriguing Stocks Priced Below Estimated ValueYahoo Finance·Dec 30, 2025
- 3 Promising Penny Stocks With A Market Cap Below $400MYahoo Finance·Dec 30, 2025
- Celsius Holdings Among 3 Value Stocks Trading Below Estimated WorthYahoo Finance·Dec 30, 2025
- Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To ProfitabilityYahoo Finance·Dec 29, 2025
- Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) ProgramsYahoo Finance·Dec 6, 2025
- Penny Stocks To Consider In December 2025Yahoo Finance·Dec 1, 2025
- Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ...Yahoo Finance·Nov 12, 2025
- Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 12, 2025
- Prelude Therapeutics (PRLD): Valuation Snapshot Following Incyte Deal and Pipeline RealignmentYahoo Finance·Nov 8, 2025
All 20 articles loaded
Price Data
Open$4.78
Previous Close$4.67
Day High$4.84
Day Low$4.32
52 Week High$5.54
52 Week Low$0.75
52-Week Range
$0.75$5.54
$4.84
Fundamentals
Market Cap$385M
P/E Ratio—
EPS$-1.29
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin—
Debt / Equity—
Trading
Volume708K
Avg Volume (10D)—
Shares Outstanding64.9M
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—